Next, we evaluated the therapeutic potential of co‐targeting PLK1 and FGFR in KRAS‐mutant cancer cells, with KRAS wild‐type cancer cells, malignant pleural mesothelioma (MPM) cells, and non‐transformed normal cells (Appendix Table S3) tested in parallel for comparison. The gene discussed is KRAS; the disease is cancer.